September 19, 2014 1:13 PM ET

Healthcare Equipment and Supplies

Company Overview of BioCardia, Inc.

Company Overview

BioCardia, Inc., a medical device company, designs, develops, manufactures, and distributes minimally invasive tools for cardiovascular therapies. It offers devices to enable percutaneous delivery of biologics to treat cardiovascular diseases. It offers helix biotherapeutic delivery products, including percutaneous catheter delivery systems for cardiovascular regenerative medicine that enables local delivery of cell, gene, and protein based therapies to treat heart failure, myocardial infarction, ischemia, and cardiac conduction disorders. The company also provides advanced catheter products for interventional medicine, which include steerable thin walled catheter shaft technology solutions ...

125 Shoreway Road

Suite B

San Carlos, CA 94070

United States

Founded in 1999





Key Executives for BioCardia, Inc.

Chief Executive Officer
Age: 48
Chief Financial Officer
Age: 54
Director of Research and Development
Director Of Quality Assurance
Vice President of Operations
Compensation as of Fiscal Year 2014.

BioCardia, Inc. Key Developments

CellProThera and BioCardia Sign Agreement to Partner on the EXCELLENT Trial

CellProThera and BioCardia announced an agreement to partner on the EXCELLENT (Expanded Cell Endocardiac Transplantation) Trial, controlled Phase I/IIb study to evaluate the safety and efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand(R) Automated Process and delivered via the BioCardia Helix(TM) Transendocardial Delivery System. The agreement calls for payments to BioCardia, which are creditable to a future clinical development program, and payments to CellProThera for timely completion of the Phase II study. The trial will study patients with an acute myocardial infarction (AMI) and a left ventricle ejection fraction (LVEF) remaining below or equal to 45% after percutaneous transluminal coronary angioplasty (PTCA) and stent(s) implantation versus standard of care. The study will encompass 44 patients treated at up to eight centers in the United Kingdom and France and followed for six months. Co-principal investigators are Jerome Roncalli, MD, PhD, Department of Cardiology, University Hospital of Toulouse, France, and David E. Newby, MD, PhD, University Centre for Cardiovascular Science of Edinburgh, Scotland. The primary endpoint of the study is no treatment emergent major adverse cardiac events (MACE) at 30 days post-procedure. Secondary endpoints will assess the first efficacy trends, the viability of the infarcted segments, safety of the Helix transendocardial delivery procedure and quality of life. In order to simplify and standardize the cell graft production process, CellProThera developed an Automated Process using a cell expansion automate StemXpand(R) and disposable kit StemPack(R). This enables GMP production of as many stem cells as those obtained with one leukapheresis, starting from a whole autologous blood sample simply drawn after G-CSF mobilization, thus avoiding leukapheresis sessions. In pre-clinical studies, the expanded CD34+ cells (Protheracytes(R)) have demonstrated the same therapeutic efficacy as naive cells with no chromosomic alteration, toxicity or tumorogenicity. The Helix Transendocardial Delivery System is a steerable, two-catheter system that enables delivery of biologic therapies to the heart muscle from within the chamber of the heart. The system's unique performance advantages include crossing the aortic valve over a wire to prevent damage; enhanced navigation using the company's steerable Morph(R) guiding catheter; a helical needle which screws into the myocardium for stable delivery; and the use of contrast at the base of the needle to confirm tissue engagement.

BioCardia, Inc. Receives CE Mark for New Helix Transendocardial Delivery Catheter

BioCardia, Inc. announced receipt of the CE Mark for its Helix 953L Catheter as part of its Helix Transendocardial Delivery System for infusion of biologics to the heart. The new catheter is optimized for larger, dilated hearts, while maintaining compatibility with smaller hearts. It also does not require biotherapeutic programs already using the Helix system for delivery to develop new compatibility data. The Helix 953L catheter will be commercially available in the European Union in the coming months. The Helix Transendocardial Delivery System is a steerable, two-catheter system that enables delivery of biologic therapies to the heart muscle from within the chamber of the heart. The catheter design minimizes the risks associated with navigating within the heart, while reducing procedure times. A helical-shaped needle screws into the myocardium for stable delivery, and contrast delivered from the needle confirms engagement with targeted tissue. The Helix Transendocardial Delivery System has received the CE Mark and is commercially available in the European Union. It is currently being used for investigational biotherapeutic programs in the United States and is not approved for sale in the U.S.

BioCardia, Inc. Announces Positive 12-Month Results for the Randomized Transendocardial Autologous Cells in Ischemic Heart Failure Trial

BioCardia(R), Inc. announced positive 12-month results for the randomized Transendocardial Autologous Cells (MSC or BMC) in Ischemic Heart Failure Trial (TAC-HFT). The Phase II trial demonstrated the safety of transendocardial stem cell injection (TESI) of autologous culture-expanded mesenchymal cells (MSCs) and autologous minimally-processed whole bone marrow mononuclear cells (BMCs) delivered by the company's Helical Infusion Catheter System(TM) in the treatment of chronic ischemic cardiomyopathy (ICM). The trial results were concurrently reported in the Journal of the American Medical Association (JAMA) and presented by lead investigator Joshua Hare, MD from the University of Miami as a late-breaking presentation at the American Heart Association's 2013 Scientific Sessions. The TAC-HFT Trial is a Phase I/II randomized, double-blind, placebo-controlled study of 65 patients with chronic ischemic left ventricular (LV) dysfunction due to ischemic cardiomyopathy (ICM), co-sponsored by the University of Miami and BioCardia. Patients were randomized to receive a dose of 200 million stem cells of either MSCs or BMCs delivered to 10 LV sites in the myocardium via TESI using the Helical Infusion Catheter System. This precise approach to infusion combines an ultra-flexible distal catheter, a helix-shaped needle to fixate to the myocardial tissue, and contrast delivered from the needle base to confirm engagement with the tissue. Both therapies met the primary endpoint of the trial by demonstrating no incidence of treatment-emergent serious adverse events (TE-SAEs) at 30 days. TE-SAEs were defined as the composite of death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade or sustained ventricular arrhythmias (>15 seconds or causing hemodynamic compromise). No significant post-procedural pericardial effusion was evident, and the technical success of transendocardial infusion with the Helical Infusion Catheter was 100%.

Similar Private Companies By Industry

Company Name Region
Electro-Catheter Corp. United States
Glaukos Corporation United States
American Medical Concepts, Inc. United States
RF Technologies, Inc. United States
Clear Image Technology, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BioCardia, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at